Meeting News CoverageVideo

VIDEO: Venetoclax represents ‘exciting advance’ in CLL

ORLANDO, Fla. — Steven T. Rosen, MD, provides insights into a study presented at ASH Annual Meeting and Exposition that showed venetoclax monotherapy conferred sustained remissions and produced a high overall response rate in patients with relapsed and/or refractory chronic lymphocytic leukemia with 17p deletion.

ORLANDO, Fla. — Steven T. Rosen, MD, provides insights into a study presented at ASH Annual Meeting and Exposition that showed venetoclax monotherapy conferred sustained remissions and produced a high overall response rate in patients with relapsed and/or refractory chronic lymphocytic leukemia with 17p deletion.

    See more from ASH Annual Meeting and Exposition